CDKN2A, also known as cyclin-dependent kinase inhibitor 2A, is a gene which in humans is located at chromosome 9, band p21.3. [5] It is ubiquitously expressed in many tissues and cell types. [6] The gene codes for two proteins, including …

Jul 17, 2023 · What is my cancer risk if I have a CDKN2A mutation? If you have a mutation in the CDKN2A gene, this means you have a condition called Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome. FAMMM syndrome increases your …

Dec 24, 2024 · CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) is a Protein Coding gene. Diseases associated with CDKN2A include Melanoma, Cutaneous Malignant 2 and Melanoma-Pancreatic Cancer Syndrome.

The CDKN2A gene provides instructions for making several proteins. The most well-studied are the p16 (INK4A) and the p14 (ARF) proteins. Both function as tumor suppressors, which means they keep cells from growing and dividing too rapidly or in an uncontrolled way.

Mar 13, 2025 · An inherited CDKN2A mutation may affect your options for cancer prevention, detection and treatment. Learn more here. FORCE is here to guide you.

Jan 1, 1997 · CDKN2A, the gene encoding the cell-cycle inhibitor p16CDKN2A, was first identified in 1994. Since then, somatic mutations have been observed in many cancers and germline alterations have been found in kindreds with familial atypical multiple mole/melanoma (FAMMM), also known as atypical mole syndrome.

Mar 25, 2021 · CDKN2A (cyclin dependent kinase inhibitor 2A, OMIM 600160) is a tumor suppressor gene that encodes for two proteins, namely p16 INK4A and p14 ARF, critical for the regulation of cell cycle pathways.

CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model.

The CDKN2A gene encodes proteins that regulate 2 critical cell cycle regulatory pathways, the p53 (TP53; 191170) pathway and the RB1 pathway. Through the use of shared coding regions and alternative reading frames, the CDKN2A gene produces 2 major proteins: p16(INK4), which is a cyclin-dependent kinase inhibitor, and p14(ARF), which binds the ...

CDKN2A is commonly altered in human cancers, but prior studies have provided conflicting evidence regarding the association between CDKN2A genomic alterations (GAs) and response to ICIs.